Grace Therapeutics GRCE
NASDAQ GRCE
$1.97 -0.01 (-0.51%)
At close: Oct 21, 2026 · 4:00 PM EDT

Grace Therapeutics (GRCE) Restructuring Costs (2023)

Updated

Grace Therapeutics' Restructuring Costs was $1.49 million in FY2024 (year ended Mar 31, 2024).

Analysis

Grace Therapeutics (GRCE) Restructuring Costs (2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Grace Therapeutics 34.02 Mn -32.25 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2023 1.49 Mn
API Access

Grace Therapeutics Restructuring Costs API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=restructuring-costs&ticker=GRCE&period=max&api_key=YOUR_API_KEY